The NF-kB pathway (nuclear factor 'kappa-light-chain-enhancer') is a well described pathway in diverse cells. Since the dysregulation of this pathway can favour cancer development, the protein cascade is well described. There are two types of the NF-kB pathway, depending on the proteins downstream, the canonical and the non-canonical pathway. However, the metabolic impact of the NF-kB pathway on the metabolic switch of B-cells has not been described yet. By inhibiting the canonical pathway (a subset of the NF-kB pathway) with Bay 11-7082 and SC-514 the role of this pathway will be discussed in this protocol.